CER Daily Newsfeed

Highlights from ISPOR 2025: Rewriting the Value Narrative and Expanding the HEOR Horizon

(6/4, Ramiro Gilardino, The Evidence Base) comments “...One of the most notable developments this year was the growing presence of venture capital and private equity voices in the conversation. This year, HEOR didn’t just speak to policy, it started speaking to capital. Panels featuring venture and biopharma investors revealed a growing interest in how HEOR can de-risk decision-making in early R&D. If this trend holds, this signals a potential pivot for the field. We could see a more integrated dialogue between those who fund innovation and those who evaluate it.” Full

Insights From ISPOR 2025: R In Health Technology Assessment – Is It The Future?

(6/3, Petauri Evidence, PMLiVE) comments “ISPOR’s annual meeting in Montreal this May was packed with opportunities to explore the latest trends, insights, and research in HEOR and market access. In this series, our experts share their reflections and key learnings from the conference. Kicking things off, Hannah Gillies and Jaesh Naik, from the Petauri Evidence HEOR team, explore how R is being used in health technology assessment (HTA) modelling, and what it might take for R to become the new standard.” Full

AcademyHealth's Situation Report: HHS Faces Cuts, Senate Eyes Medicaid, and Resources for Advocacy

(6/3, AcademyHealth Blog) comments “In this edition of AcademyHealth's Situation Report, the administration’s FY26 budget proposal outlines a significant restructuring of HHS and reductions in discretionary funding for key health agencies...Additionally, the budget proposal calls for legislation to eliminate the Patient-Centered Outcomes Research Trust Fund (PCORTF), which funds PCORI, AHRQ, and ASPE.” Full

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

(6/4, Francesca Bruce, Pink Sheet) reports “...A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.” Subscription Required

UK: NICE Recommends Sogroya for Growth Hormone Deficiency in Children

(6/4, John Pinching, PharmaTimes) reports “The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children aged 3 to 17 years with paediatric growth hormone deficiency. The once-weekly treatment, developed by Novo Nordisk, offers an alternative to existing therapies for children experiencing growth failure due to the condition.” Full

UK: Fostering the Digital Health Tech Revolution

(6/3, Dr. Sarah Byron, NICE Blog) comments “...[W]e have proposed changes that will transform how we evaluate health technologies. Our proposals include: Merging three existing programmes into a single healthtech programme. Our interventional procedures, medical technologies evaluation and diagnostics assessment programmes will be combined. Introducing a lifecycle evaluation approach to consider technologies for early or routine use in the NHS, and to consider those already in use. Making multi-tech assessments of similar technologies with the same purpose standard practice.” Full